Table 1.
Item Code | 1 | 2 | 3 | 6 | 7 | 10 | 12 | 15 | 16 | 18 | 20 | 22 | 23 | 25 | Final Score (14 Items) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | Acute Effect | ||||||||||||||
Cochrane et al. [33] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | U | 1 | 1 | 0 | 1 | U | 1 | 0.83 |
Fleddermann and Zentgraf [34] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 1 | 1 | U | 1 | 0.92 |
Gutierrez-Davila et al. [35] | 1 | 1 | 1 | 1 | 1 | 0 | 0 | U | 1 | 1 | 0 | 1 | U | 1 | 0.75 |
Helm et al. [36] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 0 | 1 | U | 1 | 0.83 |
Howell et al. [37] | 1 | 1 | 1 | 0 | 1 | 1 | 1 | U | 1 | 1 | 1 | 0 | U | 1 | 0.83 |
Howell et al. [38] | 1 | 0 | 1 | 1 | 1 | 1 | 1 | U | 1 | 1 | 1 | 1 | U | 0 | 0.83 |
Laurin and Finez [12] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | U | 1 | 0 | 0 | 1 | U | 1 | 0.75 |
Lynall et al. [39] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 1 | 1 | U | 1 | 0.92 |
Qiu et al. [40] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 1 | 1 | U | 1 | 0.92 |
Runswick et al. [41] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 1 | 1 | 1 | 1 | 0.92 |
Schaefer and Scornaienchi [42] | 1 | 1 | 1 | 1 | 0 | 1 | 1 | U | 1 | 1 | 1 | 1 | U | 1 | 0.92 |
Tapper et al. [43] | 1 | 1 | 1 | 1 | 1 | 1 | 0 | U | 1 | 1 | 1 | 1 | U | 1 | 0.92 |
Van Biesen et al. [44] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | U | 1 | 1 | 1 | 1 | U | 1 | 1 |
Chronic Effect | |||||||||||||||
Ducrocq et al. [45] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | U | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Fleddermann et al. [21] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | U | 1 | 1 | 1 | 1 | U | 1 | 1 |
Harris et al. [46] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | U | 1 | 1 | 1 | 1 | U | 1 | 1 |
Romeas et al. [25] | 1 | 1 | 1 | 1 | 0 | 1 | 0 | U | 1 | 1 | U | U | U | 1 | 0.8 |
Romeas et al. [26] | 1 | 1 | 1 | 1 | 0 | 1 | 0 | U | 1 | 1 | U | U | U | 1 | 0.8 |